{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cosentyx&page=3", "query": { "intervention": "Cosentyx", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 116, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cosentyx&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cosentyx&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T00:14:26.942Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03536884", "title": "A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Plaque Psoriasis", "Moderate to Severe Chronic Plaque Psoriasis" ], "interventions": [ { "name": "Bimekizumab", "type": "DRUG" }, { "name": "Secukinumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 743, "start_date": "2018-06-13", "completion_date": "2023-08-09", "has_results": true, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-11-01T00:14:26.942Z", "location_count": 25, "location_summary": "Santa Ana, California • Danbury, Connecticut • Ocala, Florida + 20 more", "locations": [ { "city": "Santa Ana", "state": "California" }, { "city": "Danbury", "state": "Connecticut" }, { "city": "Ocala", "state": "Florida" }, { "city": "Ormond Beach", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03536884" }, { "nct_id": "NCT07138898", "title": "Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatic Disease" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Golimumab", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Belimumab", "type": "BIOLOGICAL" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" }, { "name": "Anakinra", "type": "BIOLOGICAL" }, { "name": "Canakinumab", "type": "BIOLOGICAL" }, { "name": "Abatacept", "type": "BIOLOGICAL" }, { "name": "Secukinumab", "type": "BIOLOGICAL" }, { "name": "Ixekizumab", "type": "BIOLOGICAL" }, { "name": "Bimekizumab", "type": "BIOLOGICAL" }, { "name": "Ustekinumab", "type": "BIOLOGICAL" }, { "name": "Guselkumab", "type": "BIOLOGICAL" }, { "name": "Risankizumab", "type": "BIOLOGICAL" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2025-12-12", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-11-01T00:14:26.942Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07138898" }, { "nct_id": "NCT03079531", "title": "Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Papulopustular Rosacea" ], "interventions": [ { "name": "Secukinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anne Chang", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2017-06-21", "completion_date": "2019-01-25", "has_results": true, "last_update_posted_date": "2020-02-05", "last_synced_at": "2026-11-01T00:14:26.942Z", "location_count": 1, "location_summary": "Redwood City, California", "locations": [ { "city": "Redwood City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03079531" }, { "nct_id": "NCT07237594", "title": "IL-17 Blockade to Decrease irAEs (REPLAY)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Secukinumab Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2026-03-12", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-11-01T00:14:26.942Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07237594" }, { "nct_id": "NCT00685399", "title": "Safety and Efficacy of AIN457 in Noninfectious Uveitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-infectious Uveitis" ], "interventions": [ { "name": "AIN457", "type": "DRUG" }, { "name": "AIN 457", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 76, "start_date": "2008-06", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2017-07-17", "last_synced_at": "2026-11-01T00:14:26.942Z", "location_count": 20, "location_summary": "Beverly Hills, California • Los Angeles, California • Sacramento, California + 16 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Golden", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00685399" }, { "nct_id": "NCT02594098", "title": "Secukinumab for Treatment of Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Secukinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2015-11", "completion_date": "2018-01-30", "has_results": true, "last_update_posted_date": "2019-06-12", "last_synced_at": "2026-11-01T00:14:26.942Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02594098" }, { "nct_id": "NCT05722522", "title": "Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rotator Cuff Tendinopathy" ], "interventions": [ { "name": "Secukinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 33, "start_date": "2023-08-10", "completion_date": "2024-12-13", "has_results": true, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-11-01T00:14:26.942Z", "location_count": 6, "location_summary": "Westlake Village, California • Miami, Florida • Plantation, Florida + 3 more", "locations": [ { "city": "Westlake Village", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Plantation", "state": "Florida" }, { "city": "Sunrise", "state": "Florida" }, { "city": "Morehead City", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05722522" }, { "nct_id": "NCT01807520", "title": "Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Nail Psoriasis" ], "interventions": [ { "name": "Secukinumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 198, "start_date": "2013-06-20", "completion_date": "2017-01-03", "has_results": true, "last_update_posted_date": "2018-03-13", "last_synced_at": "2026-11-01T00:14:26.942Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Skokie, Illinois + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "High Point", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01807520" }, { "nct_id": "NCT01555125", "title": "First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Plaque-type Psoriasis" ], "interventions": [ { "name": "secukinumab 150 mg", "type": "DRUG" }, { "name": "secukinumab 300 mg", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 177, "start_date": "2012-05-08", "completion_date": "2016-10-24", "has_results": true, "last_update_posted_date": "2018-08-08", "last_synced_at": "2026-11-01T00:14:26.942Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01555125" }, { "nct_id": "NCT01649375", "title": "16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anklyosing Spondylitis" ], "interventions": [ { "name": "Secukinumab (75 mg)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Secukinumab (150 mg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 219, "start_date": "2012-10-18", "completion_date": "2018-09-18", "has_results": true, "last_update_posted_date": "2019-10-30", "last_synced_at": "2026-11-01T00:14:26.942Z", "location_count": 10, "location_summary": "Mesa, Arizona • Upland, California • Edina, Minnesota + 6 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Upland", "state": "California" }, { "city": "Edina", "state": "Minnesota" }, { "city": "Tupelo", "state": "Mississippi" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01649375" } ] }